Use of ACE inhibitor and ARB substitutes could have saved Medicare $676 million in 2016-2017
Broader use of generic angiotensin-II-receptor blockers (ARBs) and angiotensin converting enzyme (ACE) inhibitors for hypertension and congestive heart failure could yield millions in healthcare savings, a new study suggested.